What Is the Hemopurifier and How Does It Work?
Aethlon Medical (NASDAQ: AEMD) presented at the Life Sciences Virtual Investor Forum on March 12, 2026, outlining a bold vision for its flagship medical device — the Hemopurifier. CEO and CFO Jim Frakes led the session, moderated by M. Marin of Zacks Small Cap Research.
The Hemopurifier targets harmful particles in the bloodstream. Specifically, it removes extracellular vesicles (EVs) — nanoparticles released by all cell types — and harmful viruses. The device connects to a standard blood pumping system, such as a dialysis or CRRT machine found in hospitals worldwide.
How the Filtration Process Works
Inside the Hemopurifier are approximately 20,000 tiny fibers. The plasma passes through those fibers, where diatomaceous earth bound to a plant lectin captures the sugary surface coating of viruses and EVs. The cleaned plasma then returns to the body. Each treatment session typically lasts four hours. Each pass removes more harmful particles, giving the immune system a stronger chance to fight disease.
The FDA has granted the device Breakthrough Device designation for two key areas: life-threatening viruses with no prescribed therapy and life-threatening oncologic conditions. Furthermore, the company has recorded 173 Hemopurifier treatments across 44 patients, with no serious device-related adverse events reported.
Oncology Focus: Why Cancer Is the Priority
The Role of Extracellular Vesicles in Cancer
EVs play a damaging role in cancer progression. Research shows they contribute to metastasis (the spread of cancer), angiogenesis (growth of new blood vessels to tumors), apoptosis (cell death), suppression of cancer-fighting T-cells, and resistance to chemotherapy and immunotherapy drugs.
Aethlon’s hypothesis is straightforward: removing EVs from a cancer patient’s bloodstream could reduce metastasis and improve the effectiveness of existing treatments. This approach targets a critical gap in current oncology care.
Why Keytruda and Opdivo Are Central to the Strategy
Aethlon focuses its trial around two blockbuster immunotherapy drugs — Keytruda and Opdivo. Together, they rank among the world’s best-selling medications, with Keytruda alone generating approximately $25 billion in annual sales. Yet both drugs work in only around one-third of patients. The remaining two-thirds receive little benefit.
Aethlon’s strategy aims to help patients who fall into that unresponsive two-thirds. Even a modest improvement in response rates — just one to two percentage points — would translate to thousands of additional patients benefiting from treatment, given the enormous size of the market. The Hemopurifier treatments occur before each patient’s scheduled Keytruda or Opdivo session, making it a complementary rather than competing therapy.
Australia Clinical Trial: Progress and Milestones
Trial Design and Current Status
The ongoing safety trial takes place in Australia, structured around nine patients divided into three cohorts. The first cohort received one treatment each. The second cohort received two treatments within a week. The third cohort, once approved, will receive three treatments in a single week — scheduled Monday, Wednesday, and Friday.
Two cohorts are now complete. The independent Data Safety Monitoring Board (DSMB) has approved progression from cohort one to cohort two. A DSMB meeting later in March 2026 will determine whether the trial advances to cohort three. Three patients are already in the queue, pending that approval.
Why Australia Was Chosen
Three factors made Australia the ideal trial location. First, Australian clinicians offer world-class medical expertise. Second, Chief Medical Officer Dr. Steven LaRosa has prior experience running clinical trials there. Third — and significantly — Australia offers a 43% cash reimbursement on all trial expenses. This incentive substantially reduces costs for a resource-conscious company like Aethlon.
Moreover, data generated in Australia is expected to gain FDA acceptance. The company also plans to apply to Australia’s Therapeutic Goods Administration (TGA) following trial completion.
Key Milestones to Watch
Investors should track the following events over the next 12 to 18 months:
- DSMB decision on advancing to cohort three
- Data release from cohorts two and three
- Completion of the full safety trial
- Initiation of the larger efficacy trial (phase two for devices)
Unlike drug trials requiring thousands of participants, medical device trials require just two stages — safety and efficacy — with far fewer patients involved.
Financial Position and Cash Runway
Strong Balance Sheet, Disciplined Spending
Aethlon closed the December quarter with just under $7 million in cash and zero debt. The quarterly burn rate stands at approximately $1.5 million — or $500,000 per month — giving the company more than four quarters of runway at the current pace. Additionally, $1.85 million remains available through an at-the-market (ATM) facility.
Part of the burn rate is variable, tied directly to the number of patient treatments. As trial activity increases, spending may rise accordingly. However, Frakes expressed confidence in the company’s financial position, noting that current resources are sufficient to complete the safety trial.
Manufacturing takes place at the company’s facility in San Diego, which can scale production to meet growing trial demands. Currently, the team produces devices three to four times per year — enough to support ongoing trial needs.
Strategic Partnerships and Future Growth
Engaging Maxim to Secure a Partner
Moving from the safety trial to the larger efficacy trial requires additional resources. To address this, Aethlon engaged investment bank Maxim to identify strategic and financing partners. The company announced this engagement via press release on the morning of the forum.
The ideal partner would bring industry knowledge, financial strength, and an understanding of the oncology market. A strategically aligned partner could accelerate the path to a larger trial and, ultimately, commercial approval.
A Simpler Blood Pumping System on the Horizon
Aethlon is collaborating with another company to develop a simplified blood pumping system. Currently, the Hemopurifier requires a dual lumen catheter and a trained dialysis nurse or nephrologist. The new system would work through standard IV catheters used in routine hospital care, making the device accessible to virtually any healthcare professional.
This simplified system is still in early development and does not yet have FDA approval. Nevertheless, it could dramatically expand the device’s reach across clinical settings if successful.
Exploring Other Therapeutic Areas
While oncology remains the primary focus, Aethlon continues to explore adjacent applications. These include long COVID (in collaboration with UC San Francisco), autoimmune diseases such as lupus and rheumatoid arthritis via platelet-derived EVs, and chronic kidney disease, where EVs from damaged kidneys contribute to heart complications. Grant funding may support future work in these areas.
Market Opportunity and Investor Outlook
The addressable market for oncology devices is substantial. Keytruda and Opdivo alone serve millions of patients globally. If the Hemopurifier can improve immunotherapy response rates — even modestly — the commercial opportunity is significant. Frakes acknowledged the high-risk, high-reward nature of the investment clearly. Yet early data from cohort one showed T-cell and EV markers moving in the desired direction, offering encouraging signs.
Critically, the Hemopurifier is currently the only device known to remove EVs from the bloodstream. This makes it a genuinely differentiated treatment option with no direct competitors in this specific mechanism.
